Literature DB >> 12704351

Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide.

Ensio Norjavaara1, Maria Gerhardsson de Verdier.   

Abstract

BACKGROUND: Inhaled corticosteroids are recommended as first-line therapy for pregnant women with moderate to severe asthma, although the effects on pregnancy outcome are uncertain. A low compliance with the recommendations might lead to inadequate control of asthma, which has been associated with adverse outcomes both for the mother and the infant.
OBJECTIVE: To investigate whether the reported use of inhaled budesonide (Pulmicort) during pregnancy influences birth outcome.
METHODS: Data were derived from the Swedish Medical Birth Register, which includes 99% of births in Sweden. During 1995 to 1998, 293,948 newborn infants were identified. Pregnancy outcomes were compared for mothers in Sweden reporting asthma medication usage with those reporting no asthma medication usage.
RESULTS: The 2,968 mothers who reported use of inhaled budesonide during early pregnancy gave birth to infants of normal gestational age, birth weight, and length, with no increased rate of stillbirths or multiple births. The rate of caesarean births was higher among mothers who used asthma medication during their pregnancy than among the control group.
CONCLUSIONS: The use of inhaled budesonide in Sweden is not linked with any clinically relevant effects associated with pregnancy outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704351     DOI: 10.1067/mai.2003.1340

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  22 in total

Review 1.  Fertility and pregnancy in the patient with inflammatory bowel disease.

Authors:  U Mahadevan
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

2.  European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.

Authors:  R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 3.  Safety of intranasal corticosteroid sprays during pregnancy: an updated review.

Authors:  Ahmed H Alhussien; Riyadh A Alhedaithy; Saad A Alsaleh
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-21       Impact factor: 2.503

Review 4.  Safety of inhaled corticosteroids in the treatment of persistent asthma.

Authors:  Stephen P Peters
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

Review 5.  Treating allergic rhinitis in pregnancy.

Authors:  Vincent Piette; Jean-Pierre Daures; Pascal Demoly
Journal:  Curr Allergy Asthma Rep       Date:  2006-05       Impact factor: 4.806

6.  Gastrointestinal Conditions during Pregnancy.

Authors:  Sherri A Longo; Robert C Moore; Bernard J Canzoneri; Alfred Robichaux
Journal:  Clin Colon Rectal Surg       Date:  2010-06

Review 7.  Therapy of complicated Crohn's disease during pregnancy--an interdisciplinary challenge.

Authors:  C Seifarth; J P Ritz; U Pohlen; A J Kroesen; B Siegmund; B Frericks; H J Buhr
Journal:  Int J Colorectal Dis       Date:  2014-05-04       Impact factor: 2.571

Review 8.  Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation.

Authors:  Gary A Incaudo
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

Review 9.  Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk?

Authors:  D Oren; I Nulman; M Makhija; S Ito; Gideon Koren
Journal:  Can Fam Physician       Date:  2004-08       Impact factor: 3.275

Review 10.  Update in the treatment of asthma during pregnancy.

Authors:  Jennifer Altamura Namazy; Michael Schatz
Journal:  Clin Rev Allergy Immunol       Date:  2004-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.